Deal Library / Pharma BD Deal Intelligence

Pharma Deals of 2018

The Pharma Closeout tracks 165 deals, $193.3B in disclosed deal value, 40 with a post-close Outcome Score for the year 2018.

Median Critic Score: 75  ·  Median Outcome Score: 52

Best outcome: Novartis AG / Endocyte, Inc. (96)  ·  Weakest outcome: Takeda Pharmaceutical Company Ltd. / Shire plc (8)

All 165 deals

• Novartis AG / Endocyte, Inc. — 2018 · $2.1B · Worked — the deal delivered on its rationale.
• Servier / Shire plc (Oncology Business) — 2018 · $2.4B · Worked — the deal delivered on its rationale.
• Roche Holding AG / Foundation Medicine, Inc. — 2018 · $5.3B · Worked — the deal delivered on its rationale.
• Merck & Co. Inc. / Eisai Co., Ltd. — 2018 · $5.8B · Worked — the deal delivered on its rationale.
• Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) — 2018 · $2.3B · Worked — the deal delivered on its rationale.
• GlaxoSmithKline plc / Tesaro Inc. — 2018 · $5.1B · Worked — the deal delivered on its rationale.
• Boston Scientific Corporation / BTG plc — 2018 · $4.2B · Worked — the deal delivered on its rationale.
• GSK plc / Pfizer Inc. — 2018 · $0.0M · Worked — the deal delivered on its rationale.
• GlaxoSmithKline plc / Pfizer Inc. (Consumer Healthcare Division) — 2018 · $12.7B · Worked — the deal delivered on its rationale.
• GlaxoSmithKline plc / Novartis Consumer Healthcare JV — 2018 · $13.0B · Largely worked — most objectives met.
• Sanofi SA / Translate Bio Inc. — 2018 · $805M · Largely worked — most objectives met.
• Celgene Corporation / Bristol-Myers Squibb Company — 2018 · $9.0B · Largely worked — most objectives met.
• Novartis AG / AveXis Inc. — 2018 · $8.7B · Largely worked — most objectives met.
• Sanofi SA / Ablynx NV — 2018 · $4.8B · Largely worked — most objectives met.
• Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. — 2018 · $1.2B · Largely worked — most objectives met.
• Orchard Therapeutics Limited / GlaxoSmithKline plc — 2018 · Largely worked — most objectives met.
• Pfizer Inc. / BioNTech SE — 2018 · $425M · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Bioverativ Inc. — 2018 · $11.6B · Mixed — partial payoff, real shortfalls.
• AstraZeneca PLC / Innate Pharma SA — 2018 · $1.3B · Mixed — partial payoff, real shortfalls.
• Celgene Corporation / Impact Biomedicines — 2018 · $7.0B · Mixed — partial payoff, real shortfalls.
• Roche Holding AG / Flatiron Health — 2018 · $1.9B · Mixed — partial payoff, real shortfalls.
• Al Sirona (Luxembourg) Acquisition / Zentiva Group — 2018 · $2.4B · Mixed — partial payoff, real shortfalls.
• Dr. Max / Sensiblu — 2018 · $415M · Mixed — partial payoff, real shortfalls.
• Akebia Therapeutics, Inc. / Keryx Biopharmaceuticals, Inc. — 2018 · $1.3B · Underwhelmed — fell short of the thesis.
• Mylan N.V. / Novartis AG (TOBI franchise) — 2018 · $463M · Underwhelmed — fell short of the thesis.
• GSK plc / 23andMe, Inc. — 2018 · $300M · Underwhelmed — fell short of the thesis.
• GlaxoSmithKline plc / 23andMe, Inc. — 2018 · $300M · Underwhelmed — fell short of the thesis.
• Eli Lilly and Company / Sigilon Therapeutics Inc. — 2018 · $1.8B · Underwhelmed — fell short of the thesis.
• Mereo BioPharma Group plc / OncoMed Pharmaceuticals, Inc. — 2018 · $57M · Did not work — the deal failed to deliver.
• Akcea Therapeutics, Inc. / Ionis Pharmaceuticals, Inc. — 2018 · $1.7B · Did not work — the deal failed to deliver.
• Roche Holding AG / Tusk Therapeutics — 2018 · $759M · Did not work — the deal failed to deliver.
• Bristol-Myers Squibb Company / Nektar Therapeutics — 2018 · $3.6B · Did not work — the deal failed to deliver.
• Astellas Pharma Inc. / Mitobridge, Inc. — 2018 · $450M · Did not work — the deal failed to deliver.
• Takeda Pharmaceutical Company Ltd. / Wave Life Sciences Ltd. — 2018 · $2.0B · Did not work — the deal failed to deliver.
• Alexion Pharmaceuticals Inc. / Wilson Therapeutics AB — 2018 · $855M · Did not work — the deal failed to deliver.
• Eli Lilly and Company / ARMO BioSciences Inc. — 2018 · $1.6B · Did not work — the deal failed to deliver.
• H. Lundbeck A/S / Prexton Therapeutics BV — 2018 · $1.1B · Did not work — the deal failed to deliver.
• Alexion Pharmaceuticals Inc. / Syntimmune, Inc. — 2018 · $1.2B · Did not work — the deal failed to deliver.
• Takeda Pharmaceutical Company Ltd. / TiGenix NV — 2018 · $640M · Did not work — the deal failed to deliver.
• Takeda Pharmaceutical Company Ltd. / Shire plc — 2018 · $62.0B · Did not work — the deal failed to deliver.
• Pint Pharma / Onconova Therapeutics — 2018
• AMAG Pharmaceuticals / Perosphere Pharmaceuticals — 2018
• Los Altos Pharmaceuticals / Sedor Pharmaceuticals — 2018
• MedImmune / Innate Pharma SA — 2018
• TRACON Pharmaceuticals / I-Mab Biopharma — 2018
• MEI Pharma / BeiGene — 2018
• Sarepta Therapeutics / Lysogene — 2018
• Green Cross LabCell / Feldan Therapeutics — 2018
• InvaGen Pharmaceuticals / Avenue Therapeutics — 2018
• Daiichi Sankyo / Merck & Co. — 2018
• VistaGen Therapeutics / Pherin Pharmaceuticals — 2018
• CBT Pharmaceuticals / Crown Bioscience — 2018
• Pieris Pharmaceuticals, Inc. / Seattle Genetics, Inc. — 2018 · $1.2B
• Cerecor / Ichorion Therapeutics — 2018
• Kissei Pharmaceutical / Rigel Pharmaceuticals — 2018
• Opiant Pharmaceuticals / Sanofi — 2018
• Zhejiang Haichang Biotechnology / Rexahn Pharmaceuticals — 2018
• Abeona Therapeutics / REGENXBIO — 2018
• CBT Pharmaceuticals / Zhejiang Bossan Pharmaceutical — 2018
• Sanofi / Denali Therapeutics — 2018
• Genentech, Inc. (Roche Group) / Affimed N.V. — 2018 · $5.1B
• Genentech / Proteostasis Therapeutics — 2018
• Horizon Pharma plc / MedImmune — 2018
• Jiangsu Nhwa Pharmaceutical / Trevena — 2018
• United Therapeutics / MannKind — 2018
• AstraZeneca / Syndax Pharmaceuticals, Inc. — 2018
• Bristol Myers Squibb / Janssen Pharmaceutical Companies of Johnson & Johnson — 2018
• Aileron Therapeutics / Pfizer — 2018
• Janssen (Cilag GmbH International, J&J) / argenx SE — 2018 · $1.8B
• Ascentage Pharma / Genor Biopharma — 2018
• Brill Pharma, S.L. / Sonoma Pharmaceuticals — 2018
• BioCryst Pharmaceuticals, Inc. / Idera Pharmaceuticals, Inc. — 2018
• CStone Pharmaceuticals / Agios Pharmaceuticals — 2018
• GSK / Kymera Therapeutics — 2018
• Zenith Epigenetics / Pfizer — 2018
• Janssen Biotech / BeneVir Biopharm — 2018 · $1.0B
• ABL Bio / I-Mab Biopharma — 2018 · $100M
• Knight Therapeutics / TherapeuticsMD — 2018
• Zai Lab / Crescendo Biologics — 2018
• Eli Lilly / AurKa Pharma — 2018
• United Therapeutics / SteadyMed — 2018
• Thea / Elsalys Biotech — 2018
• Pharmadis / Genetic Immunity — 2018
• Nektar Therapeutics / Syndax Pharmaceuticals — 2018
• Biothera Pharmaceuticals / AstraZeneca — 2018
• China Oncology Focus / Auransa — 2018
• PCI Biotech / IMV — 2018
• OHM Oncology / Aptose Biosciences — 2018
• Janssen Pharmaceuticals, Inc. / Beacon Discovery — 2018
• LSK BioPharma / Jiangsu Hengrui Medicine — 2018
• Pyramid Biosciences / AstraZeneca — 2018
• Merck KGaA / Vyriad — 2018
• CSPC Pharmaceutical Group / I-Mab Biopharma — 2018
• Celgene / Prothena — 2018
• Sangamo Therapeutics / TxCell — 2018
• Genmab / Immatics Biotechnologies — 2018
• CRISPR Therapeutics / ViaCyte — 2018
• Xynomic Pharmaceuticals / Boehringer Ingelheim — 2018
• photonamic / NX Development — 2018
• Roivant Sciences / Nabriva Therapeutics — 2018
• Bliss Biopharmaceutical / Morphotek — 2018
• Amgen / Molecular Partners — 2018
• Rhythm Pharmaceuticals / Takeda Pharmaceutical — 2018
• Roivant Sciences / iNtRON Biotechnology — 2018
• Loxo Oncology / Illumina — 2018
• Endo International / Somerset Therapeutics — 2018
• Ahon Pharmaceutical / DiaMedica Therapeutics — 2018
• Daewoong Pharmaceutical / Bridge Biotherapeutics — 2018 · $40M
• Takeda Pharmaceutical / Beacon Discovery — 2018
• Aclaris Therapeutics / Allergan Sales — 2018
• Orgenesis / Hemogenyx Pharmaceuticals — 2018
• Novo Nordisk / Embark Biotech — 2018
• Immunobiochem / Advanced Proteome Therapeutics — 2018
• Amgen / Entera Bio — 2018
• ProQR Therapeutics / Ionis Pharmaceuticals — 2018
• TerSera Therapeutics / TESARO — 2018
• Mesoblast / Cartherics — 2018
• Emergent BioSolutions / PaxVax — 2018 · $270M
• Neurocrine Biosciences / Jnana Therapeutics — 2018
• Boston Pharmaceuticals / Novartis — 2018
• PTC Therapeutics / Agilis Biotherapeutics — 2018
• Santhera Pharmaceuticals / Polyphor — 2018
• Bristol Myers Squibb / Compugen — 2018
• Eli Lilly / Aduro Biotech — 2018
• Merck KGaA / Leap Therapeutics — 2018
• Kyowa Hakko Kirin / MEI Pharma — 2018
• Tolero Pharmaceuticals / AbbVie — 2018
• Valeant Pharmaceuticals International / Kaken Pharmaceutical — 2018
• AbbVie / Morphic Therapeutic — 2018
• Cipher Pharmaceuticals / Aclaris Therapeutics — 2018
• Axovant Sciences / Benitec Biopharma — 2018
• Novo Nordisk / Kallyope — 2018
• BeiGene Ltd. / Mirati Therapeutics — 2018
• Rocket Pharmaceuticals / REGENXBIO — 2018
• Genentech / Kineta Chronic Pain — 2018
• Janssen Pharmaceuticals / MeiraGTx — 2018
• Medison Pharma Ltd. / Resverlogix Corp. — 2018
• Orgenesis / MangoGen Pharma — 2018
• DNAtrix / Valo Therapeutics — 2018
• Sandoz / Biocon — 2018
• AstraZeneca / Immunomedics — 2018
• Innovent Biologics / Incyte — 2018
• Telix Pharmaceuticals / Nihon Medi-Physics — 2018
• Anji Pharmaceuticals / LipimetiX Development — 2018
• TG Therapeutics, Inc. / Jiangsu Hengrui Medicine Co., Ltd. — 2018
• Qualigen / Advanced Cancer Therapeutics — 2018
• Zai Lab / Entasis Therapeutics — 2018
• Amgen / Provention Bio — 2018
• GeoVax Labs / CaroGen — 2018
• Vifor Fresenius Medical Care Renal Pharma / Cara Therapeutics — 2018
• Oncocare Therapeutics / Quest PharmaTech — 2018
• Knight Therapeutics / Jaguar Health — 2018
• United Therapeutics / Samumed — 2018
• Bristol Myers Squibb / Infinity Pharmaceuticals — 2018
• Basilea Pharmaceutica / ArQule — 2018
• United Therapeutics / Arena Pharmaceuticals — 2018 · $1.2B
• Helix BioPharma / ProMab Biotechnologies — 2018
• Eli Lilly / NextCure — 2018
• Advanced Accelerator Applications / FUJIFILM Toyama Chemical — 2018
• Astellas Pharma / Anaeropharma Science — 2018
• Servier / Treventis — 2018
• Allergan / Bonti — 2018
• Nektar Therapeutics / Pfizer — 2018
• Takeda Pharmaceutical / Nektar Therapeutics — 2018
• Ono Pharmaceutical / Fate Therapeutics — 2018

← Deal Library  ·  Interactive search  ·  How we score deals